19sth September 2024

Mr. Harald Enzmann
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS
Amsterdam
The Netherlands

Subject: Withdrawal of Epixram (levetiracetam 1000 mg/ 1500 mg/ 2000 mg/ 3000 mg prolonged-release granules)
EMEA/H/C/006186

Dear Mr Harald Enzmann,

Following up from our initial marketing authorisation application as mentioned above, ł we would like to inform you that, at this point of the procedure, Neuraxpharm Pharmaceuticals, S.L. has taken the decision to withdraw the application for the Marketing Authorisation of **Epixram (levetiracetam 1000 mg/ 1500 mg/ 2000 mg/ 3000 mg prolonged-release granules) - EMEA/H/C/006186** which was intended to be used for the treatment of epilepsy in adults and adolescents from 16 years of age.

This withdrawal is based on some regulatory strategy reasons.

We reserve the right to make a further application for this Marketing Authorisation at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely

_____

Neuraxpharm Pharmaceuticals, S.L.